Breakthrough Therapy Designation for Roche’s Gazyva
Posted by
www.biotecnika.org
Roche's Gazyva (obinutuzumab) gets BTD in Lupus Nephritis As of the
press release on 18th September 2019, The Gazyva®(obinutuzumab) from
Roche received the Breakthrough Therapy Designation (BTD) from the
U.S. Food and Drug Administration (FDA). It is first of its kind
recognition given by the FDA for medication treating Lupus nephritis.
This designation was based […]
The post Breakthrough Therapy Designation for Roche's Gazyva appeared
first on Rasayanika .
https://www.rasayanika.com/2019/09/24/breakthrough-therapy-designation-for-roches-gazyva/
News
Subscribe to:
Post Comments (Atom)
Post a Comment